Phenotypic diversity and prognosis of adult T-cell leukemia.
We examined phenotypically 107 patients with adult T-cell leukemia (ATL), using a panel of monoclonal antibodies, in order to clarify the occurrence of aberrant phenotypes, and to determine the correlation between phenotypic diversity and prognosis. The incidence of the typical (CD4+.CD8-) phenotype, the double-negative (CD4-.CD8-), the double-positive (CD4+.CD8+), and the CD8-positive (CD4-.CD8+) phenotypes was 81%, 7%, 7%, and 4%, respectively. The median survival time (MST) for all patients was 10.0 months with 17% survival at 2 years. The patients with typical phenotypes had a 10.2 month MST with 20% survival at 2 years, significantly better than the patients with the unusual phenotypes whose MST were 4.9, 7.8, and 2.6 months, respectively, for the double-negative, double-positive, and CD8-positive phenotypes. Lack of antigens reactive with CD2, CD3, CD5, and WT31 monoclonal antibody panels was one factor in bad prognosis, but the presence of CD4 and CD8 antigen abnormalities was much more significant.
Kamihira
S
S
Blood Transfusion Service, Nagasaki University Hospital, Japan.
Sohda
H
H
Atogami
S
S
Toriya
K
K
Yamada
Y
Y
Tsukazaki
K
K
Momita
S
S
Ikeda
S
S
Kusano
M
M
Amagasaki
T
T
D015703:Antigens, CD / Q000032:analysis*; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D005260:Female; D015481:HTLV-I Antibodies / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D015458:Leukemia, T-Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D008297:Male; D010641:Phenotype; D011379:Prognosis
D015703:Antigens, CD; D015704:CD4 Antigens; D016827:CD8 Antigens; D015481:HTLV-I Antibodies